DOCSLIB.ORG

TURKEY MINISTRY of INTERIOR TURKISH NATIONAL POLICE Anti-Smuggling and Organized Crime Department

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TURKEY MINISTRY of INTERIOR TURKISH NATIONAL POLICE Anti-Smuggling and Organized Crime Department REPUBLIC OF TURKEY MINISTRY OF INTERIOR TURKISH NATIONAL POLICE Anti-Smuggling and Organized Crime Department EMCDDA 2009 ANNUAL REPORT (2008 data) Reitox National Focal Point TURKEY 2009 National Report on Counteracting Addictive Substances and Substance Addiction REITOX ANKARA 2009 REPUBLIC OF TURKEY MINISTRY OF INTERIOR TURKISH NATIONAL POLICE Anti-Smuggling and Organized Crime Department 2009 NATIONAL REPORT TO THE EMCDDA By the Reitox National Focal Point TURKEY New Developments, Trends and Selected Issues Mustafa PINARCI EMCDDA Turkey National Focal Point (TUBİM), President TABLE OF CONTENTS TABLE OF CONTENTS ........................................................................................................... 3 ABBREVIATIONS AND ACRONYMS .................................................................................. 6 SUMMARY ............................................................................................................................... 8 PART A .................................................................................................................................... 13 NEW DEVELOPMENTS AND TRENDS .............................................................................. 13 SECTION 1 .............................................................................................................................. 13 NATIONAL POLICIES AND CONTEXT ............................................................................. 13 1.1. Legal Framework .......................................................................................................... 14 1.1.1. International Agreements and Conventions ........................................................... 14 1.1.2. National Legislation ............................................................................................... 15 1.1.3. New Developments in Legal Frameworks ............................................................. 18 1.1.4. Implementation of Laws......................................................................................... 20 1.2. Strategy, Action Plan, Evaluation and Coordination .................................................... 21 1.2.1. National Strategy and Action Plan ..................................................................... 21 1.2.2. Implementation and Evaluation of the National Strategy and Action Plan ....... 22 1.2.2.1. Implementation ............................................................................................ 22 1.2.2.2. Evaluation ..................................................................................................... 23 1.2.3. Other Developments in Antidrug Policies ............................................................. 23 1.2.3.1. TGNA Research Commission ................................................................... 23 1.2.4. Coordination Arrangements ................................................................................... 23 1.2.5. Institutional Structure ............................................................................................. 26 1.3. Economic Analyses ................................................................................................... 27 SECTION 2 .............................................................................................................................. 28 DRUG USE PREVALENCE ................................................................................................... 28 2.1. Drug Use in the General Population ............................................................................. 28 2.2. Drug Use in the Youth Population ................................................................................ 28 2.3. Drug use among Specific Groups .................................................................................. 28 SECTION 3 .............................................................................................................................. 29 PREVENTION ......................................................................................................................... 29 3.1. Introduction ................................................................................................................... 29 3.2. Scope and Diversity of Addiction Preventive Activities .............................................. 30 3.3. Universal Prevention in Turkey .................................................................................... 31 3.3. Selective Prevention ...................................................................................................... 39 3.4. Conclusion ..................................................................................................................... 45 SECTION 4 .............................................................................................................................. 46 PROBLEM DRUG USE AND TREATMENT DEMAND ..................................................... 46 4.1.Overview ........................................................................................................................ 46 SECTION 5 .............................................................................................................................. 49 SUBSTANCE ADDICTION TREATMENT .......................................................................... 49 5.1. Introduction ................................................................................................................... 49 5.2. Strategy and Policy ........................................................................................................ 49 5.2.1. New Developments and Trends ............................................................................. 49 5.3. Treatment Systems ........................................................................................................ 50 5.3.1. Treatment Approach ............................................................................................... 51 5.3.2. Treatment Quality .................................................................................................. 52 5.3.3. Treatment without Pharmacological Assistance .................................................... 53 5.3.4. Medical Treatment ................................................................................................. 54 5.4. Profile of Clients in Treatment ...................................................................................... 55 SECTION 6 .............................................................................................................................. 65 HEALTH CORRELATES AND CONSEQUENCES ............................................................. 65 6.1. Drug-related Deaths and Mortality of Drug Users ........................................................ 65 6.1.1. Introduction ............................................................................................................ 65 6.1.2. Direct Drug related Deaths ..................................................................................... 66 6.1.3. Indirect Drug Related Deaths ................................................................................. 69 6.1.4. Evaluation ............................................................................................................... 70 6.2. Drug-related Infectious Diseases ................................................................................. 74 6.3. Drug-related Psychiatric Disorders ............................................................................... 76 6.4. Other Drug-related Health Correlates and Consequences ............................................. 76 SECTION 7 .............................................................................................................................. 77 RESPONSES TO HEALTH CORRELATES AND CONSEQUENCES ............................... 77 7.1. Prevention of Drug-Related Deaths .............................................................................. 77 7.2. Prevention and Treatment of Drug-Related Infectious Diseases .................................. 77 7.3. Interventions Related to Psychiatric Co-Morbidity, ..................................................... 78 7.4. Interventions Related to Other Health Correlates and Consequences ........................... 78 7.4.1. Drug-related Poisoning .......................................................................................... 78 SECTION 8 .............................................................................................................................. 81 8.1. Social Exclusion ............................................................................................................ 81 8. 2. Addicts and Reintegration ................................................................................................ 84 8.2.1.Shelter ...................................................................................................................... 85 8.2.2. Education and Training .......................................................................................... 86 8.2.3. Employment ........................................................................................................... 87 8.2.4. Basic Social Assistance .......................................................................................... 88 8.3. Conclusion ..................................................................................................................... 88 SECTION
Load more

Recommended publications
  • A Policy Perspective on the Global Use of Smokeless Tobacco
    Curr Addict Rep DOI 10.1007/s40429-017-0166-7 TOBACCO (AH WEINBERGER, SECTION EDITOR) A Policy Perspective on the Global Use of Smokeless Tobacco Kamran Siddiqi1 & Aishwarya Lakshmi Vidyasagaran1 & Anne Readshaw1 & Ray Croucher2 # The Author(s) 2017. This article is an open access publication Abstract Keywords Smokeless tobacco . Snus . Tobacco control . Background Globally, over 300 million people consume di- Global health verse smokeless tobacco (ST) products. They are addictive, cause cancer, increased cardiovascular mortality risks and poor pregnancy outcomes. Introduction Purpose of Review To identify gaps in implementing key ST demand-reduction measures, focused literature reviews were “Smokeless tobacco” (ST) comprises tobacco products that do conducted and findings synthesized according to relevant not involve a combustion process, such as chewing, nasal and WHO Framework Convention on Tobacco Control (FCTC) oral tobacco [1•]. Globally, over 300 million people consume Articles. ST [1•], yet ST has been largely neglected in research and Recent Findings The literature supports implementation of policy arenas because it is generally regarded as less harmful ST demand-reduction measures. For taxation, labelling and than cigarettes. It is also seen as a regional rather than a global packaging, most administrations have weaker policies for ST problem, and too diverse and complex to control. than cigarettes. Capacity to regulate ST contents and offer ST use is reported in at least 116 countries worldwide, cessation support is lacking. There is poor compliance with including countries in Africa, Asia, Europe and the bans on ST advertising, promotion and sponsorship. Americas [2•]. Smokeless tobacco consumption is therefore Summary The literature on implementation of WHO a global public health issue.
    [Show full text]
  • 2020 International Narcotics Control Strategy Report
    United States Department of State Bureau for International Narcotics and Law Enforcement Affairs International Narcotics Control Strategy Report Volume I Drug and Chemical Control March 2020 INCSR 2020 Volume 1 Table of Contents Table of Contents Common Abbreviations ..................................................................................................................................... iii International Agreements.................................................................................................................................... v INTRODUCTION ..................................................................................................................................... 1 Legislative Basis for the INCSR ......................................................................................................................... 2 Presidential Determination ................................................................................................................................. 7 Policy and Program Developments .................................................................................................... 12 Overview ......................................................................................................................................................... 13 Methodology for U.S. Government Estimates of Illegal Drug Production .......................................................... 18 Parties to UN Conventions ..............................................................................................................................
    [Show full text]
  • Finland Country Drug Report 2017
    Finland Country Drug Report 2017 Contents: At a glance | National drug strategy and coordination (p. 2) | Public expenditure (p. 3) | Drug laws and drug law offences (p. 4) | Drug use (p. 5) | Drug harms (p. 8) | Prevention (p. 10) | Harm reduction (p. 11) | Treatment (p. 12) | Drug use and responses in prison (p. 14) | Quality assurance (p. 15) | Drug-related research (p. 15) | Drug markets (p. 16) | Key drug statistics for Finland (p. 18) | EU Dashboard (p. 20) THE DRUG PROBLEM IN FINLAND AT A GLANCE Drug use Treatment entrants Overdose deaths Drug law offences in young adults (15-34 years) by primary drug in the last year 250 Cannabis 200 23 478 166 150 13.5 % Top 5 drugs seized 100 ranked according to quantities Cannabis, 21% 50 measured in kilograms Amphetamines, 15 % Cocaine, 0 % 0 1. Amphetamine 2011 2012 2013 2015 2014 Opioids, 52 % 2010 2007 2008 2006 9 % 17.9 % 2009 Other, 12 % 2. Herbal cannabis Other drugs Opioid substitution HIV diagnoses 3. Cannabis resin MDMA 2.5 % treatment clients attributed to injecting 4. Cocaine Amphetamines 2.4 % 14 5. Heroin Cocaine 1 % 12 3 000 10 Population 8 (15-64 years) 6 7 High-risk opioid users Syringes distributeddistributed 4 through specialised 2 3 483 757 programmes 0 13 836 2011 2012 2013 2015 2014 2010 2007 2008 2006 2009 Source: EUROSTAT (12 700 - 15 090) 5 301 000 Source: ECDC Extracted on: 26/03/2017 NB: Data presented here are either national estimates (prevalence of use, opioid drug users) or reported numbers through the EMCDDA indicators (treatment clients, syringes, deaths and HIV diagnosis, drug law offences and seizures).
    [Show full text]
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • Framework Convention on Tobacco Control (WHO FCTC) Is the First Treaty Negotiated Under the Auspices of the World Health Organization
    World Health Organization Geneva, Switzerland WHO FRAMEWORK CONVENTION ON TOBACCO CONTROL World Health Organization WHO Library Cataloguing-in-Publication Data WHO Framework Convention on Tobacco Control. 1.Tobacco - supply and distribution 2.Tobacco industry - legislation 3.Tobacco smoke pollution - prevention and control 4.Tobacco use cessation 5.Treaties I.World Health Organization. ISBN 92 4 159101 3 (LC/NLM classification: HD 9130.6) © World Health Organization 2003, updated reprint 2004, 2005 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • COVID and Beyond Dart RC Opioid Abuse
    Trends within Drug Abuse and Healthcare – COVID and Beyond Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Safety, Denver Health Executive Director, RADARS® System Professor, University of Colorado School of Medicine Competing Interests RADARS® System is the property of The Denver Health and Hospital Authority (DHHA), a political subdivision of the State of Colorado. RADARS® System is supported by subscriptions from pharmaceutical manufacturers, government and nongovernment agencies for surveillance, research, and reporting services. No subscriber participated in the conception, analysis, drafting, or review of this presentation. 2 3 What Caused the US Opioid Crisis - HHS • In the late 1990s, pharmaceutical companies reassured the medical community that patients would not become addicted to opioid pain relievers and health care providers began to prescribe them at greater rates. • Increased prescription of opioid medications led to widespread misuse of both prescription and non-prescription opioids before it came clear that these medications could indeed be highly addictive. • 2017 HHS declared a public health emergency and announced a five point strategy to combat the opioid crisis https://www.hhs.gov/opioids/about-the-epidemic/index.html 4 What Really Happened? • Health care systems and regulation • Fifth vital sign, patient “satisfaction,” etc. • Careless doctors • We knew better, but let convenience win out. • Criminal behavior • Opioid marketing • Aggressive, irresponsible • Increased supply of illicit opioids • Lack of treatment for OUD • Good, but after the fact, insufficient to meet demand • Increased demand? 5 What Happened to Rx Drug Abuse? 10 Years ago… Prescription drug abuse is the Nation's fastest-growing drug problem, and the Centers for Disease Control and Prevention has classified prescription drug abuse as an epidemic.
    [Show full text]
  • Civil Society Monitoring of Harm Reduction in Europe, 2019
    Correlation Correlation European DATA REPORT Eropean Harm Reduction R C Network C Network CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 DATA REPORT 1 CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 ® Correlation – European Harm Reduction Network, 2019. This publication of Correlation – European Harm Reduction Network is protected by copyright. Reproduction is authorised provided the source is acknowledged. Recommended citation: Tammi, T., Rigoni, R., Matičič, M., Schäffer, D., van der Gouwe, D., Schiffer, K., Perez Gayo, R., Schatz, E. (2020): Civil Society Monitoring of Harm Reduction in Europe, 2019. Data Report. Correlation European Harm Reduction Network, Amsterdam. Correlation – European Harm Reduction Network c/o Foundation De REGENBOOG GROEP Droogbak 1d 1013 GE Amsterdam The Netherlands www.correlation-net.org This project has been supported by the European Commission. Correlation - European Harm Reduction Network is co-funded by the European Union 2 Correlation European DATA REPORT Harm Reduction C Network CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 DATA REPORT 3 CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 CONTRIBUTORS Editor: The data network: Graham Shaw Albania: Genci Mucollari, Aksion Plus Austria: Alexandra Karden & Barbara Siokola, Scientific expert group: Suchthilfe Wien Tuukka Tammi (THL), Dagmar Hedrich (EMCDDA), Belgium: Peter Blanckaert & Tessa Windelinckx, Sam Shirley-Beavan (HRI), Perrine Roux (INSERM). Free Clinic Bosnia and Herzegovina: Samir Ibisevic, PROI
    [Show full text]
  • The Impact of Drug Policy on Women
    THE IMPACT OF DRUG POLICY ON WOMEN Kasia Malinowska-Sempruch & Olga Rychkova As member states of the United Nations take stock of the 02 INTRODUCTION drug control system, a number of debates have emerged among governments about how to balance international 03 WHAT THE UN AND OTHER INTERNATIONAL BODIES SAY drug laws with human rights, public health, alternatives to incarceration, and experimentation with regulation. 07 ISSUES RELEVANT TO UNGASS DEBATES This series intends to provide a primer on why governments 18 CONCLUSIONS AND RECOMMENDATIONS must not turn a blind eye to pressing human rights and public health impacts of current drug policies. 01 THE IMPACT OF DRUG POLICY ON WOMEN WHAT IS THE IMPACT OF DRUG POLICY ON WOMEN? “Who ever heard of a female drug lord? As the terms ‘kingpin’ and ‘drug lord’ denote, men are almost always at the head of major drug operations, and yet the rate of imprisonment of women for drug crimes has far outpaced that of men. Families and children suffer—but why?” –American Civil Liberties Union et al., Caught in the Net, 2005 1 1 American Civil Liberties Union (ACLU), Breaking the Chains and Brennan Center for Justice. Caught in the net: the impact of drug policies on women and families. New York, 2005. At: https://www.aclu.org/drug-law-reform/caught-net-impact-drug-policies-women-and-families. 02 THE IMPACT OF DRUG POLICY ON WOMEN INTRODUCTION In the public mind, the “war on drugs” probably conjures up a male image. In most countries, official statistics would show that men, indeed, are the majority of people who use drugs recreationally, who have problematic use, and who sell drugs.
    [Show full text]
  • Summary of Synthetic Opioid Testing Within the Department of Defense
    SUMMARY OF SYNTHETIC OPIOID TESTING WITHIN THE DEPARTMENT OF DEFENSE Tom Martin, Ph.D. Liaison to Director, DoD Drug Testing and Program Policy PERSONNEL AND READINESS PERSONNEL AND READINESS Drug Demand Reduction Program Mission and Scope Mission: Enable operational readiness, safety, and security of the Total Force by deterring illicit and prescription drug abuse through robust and dynamic drug testing; emerging drug threat surveillance; prevention, education, and outreach efforts; and development of new testing procedures. Scope: All DoD components and DoD civilians in testing designated positions (TDPs) Policies: DODI 1010.01 “Military Personnel Drug Abuse Testing Program (MPDATP)” DODI 1010.09 “DoD Civilian Employee Drug-Free Workplace Program” DODI 1010.16 “Technical Procedures for the Military Personnel Drug Abuse Testing Program (MPDATP)” PERSONNEL AND READINESS DDRP Driving Factors • Drug abuse in the general U.S. 18-25 year old male group is estimated to be 17-20%– the population from which the Service recruits their enlisted personnel • Before DoD instituted drug testing among Service personnel, drug use was a significant recurring problem – Vietnam (estimated over 5% of returning service members addicted to heroin) – 1981 CVN Nimitz aviation mishap – 14 killed, 48 injured, 7 aircraft destroyed, 11 aircraft damaged, $150M in damages, six deceased with detectable levels of marijuana • Notable increase in abuse/misuse of prescription pain medications • Personnel abusing illicit drugs or prescription medications are a safety hazard
    [Show full text]
  • Growing Like Weeds? Rethinking Albania's Culture of Cannabis
    POLICY BRIEF GROWING LIKE WEEDS? Rethinking Albania’s culture of cannabis cultivation Fatjona Mejdini and Kristina Amerhauser DECEMBER 2019 ACKNOWLEDGMENTS This publication was produced with the financial support of the United Kingdom’s Conflict, Stability and Security Fund. Its contents are the sole responsibility of The Global Initiative Against Transnational Organized Crime and do not necessarily reflect the views of the United Kingdom. Special thanks to the valuable contributions of the numerous Albanian journalists who helped compile this report, in particular Driçim Çaka and Artan Hoxha. Policy briefs on current issues in the Western Balkans will be published on a reg- ular basis by the Civil Society Observatory to Counter Organized Crime in South Eastern Europe. The briefs draw on the expertise of a local civil-society network who provide new data and contextualize trends related to organized criminal activities and state responses to them. The Observatory is a platform that connects and empowers civil-society actors in Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia and Serbia. The Observatory aims to enable civil society to identify, analyze and map criminal trends, and their impact on illicit flows, governance, development, inter-ethnic relations, security and the rule of law, and supports them in their monitoring of national dynamics and wider regional and international organized- crime trends. ABOUT THE AUTHORS Fatjona Mejdini joined the GI-TOC as a field coordinator for the Balkans in September 2018. After a career as a journalist for national media in Albania, she was awarded the Hubert H Humphrey scholarship. In 2015, she joined Balkan Insight as a correspondent, reporting from the Balkan countries.
    [Show full text]
  • Drug Market Trends: Cannabis Opioids
    DRUG MARKET TRENDS: CANNABIS 3 OPIOIDS © United Nations, June 2021. All rights reserved worldwide. ISBN: 9789211483611 WORLD DRUG REPORT 2021 REPORT DRUG WORLD eISBN: 9789210058032 United Nations publication, Sales No. E.21.XI.8 This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. The United Nations Office on Drugs and Crime (UNODC) would appreciate receiving a copy of any publication that uses this publication as a source. Suggested citation: World Drug Report 2021 (United Nations publication, Sales No. E.21.XI.8). No use of this publication may be made for resale or any other commercial purpose whatsoever without prior permission in writing from UNODC. Applications for such permission, with a statement of purpose and intent of the reproduction, should be addressed to the Research and Trend Analysis Branch of UNODC. DISCLAIMER The content of this publication does not necessarily reflect the views or policies of UNODC or contributory organizations, nor does it imply any endorsement. Comments on the report are welcome and can be sent to: Division for Policy Analysis and Public Affairs United Nations Office on Drugs and Crime PO Box 500 1400 Vienna Austria Tel: (+43) 1 26060 0 Fax: (+43) 1 26060 5827 E-mail: [email protected] 2 Website: www.unodc.org/unodc/en/data-and-analysis/wdr2021.html PREFACE 3 Drugs cost lives. unemployment and inequalities, as the world lost 114 million jobs in 2020. In doing, so it has created conditions that leave In an age when the speed of information can often outstrip more people susceptible to drug use and to engaging in illicit Preface the speed of verification, the COVID-19 pandemic has taught crop cultivation.
    [Show full text]
  • Master's Dissertation
    M.A. in International Relations, Department of Political Science Security Studies Master’s Dissertation Security and health threats posed by drug trafficking from Afghanistan to the EU and the Russian Federation and mechanisms of cooperation in combating it: a case-study analysis of the current and future development of the 'Caucasus Route' Candidate: Romina Bulgaru (628562) Supervisor: Carlo Magrassi Co-supervisor: Elena Sciso Rome 2017 1 FEDERAL STATE AUTONOMOUS INSTITUTION OF HIGHER EDUCATION “MOSCOW STATE INSTITUTE OF INTERNATIONAL RELATIONS (MGIMO-UNIVERSITY), THE MINISTRY OF FOREIGN AFFAIRS OF RUSSIA” M.A. in International Relations Program “Governance and Global Affairs” Master’s Dissertation Security and health threats posed by drug trafficking from Afghanistan to the EU and the Russian Federation and mechanisms of cooperation in combating it: a case-study analysis of the current and future development of the 'Caucasus Route' Done by Romina Bulgaru Supervisor: Yulia Nikitina Moscow 2017 2 ACKNOWLEDGEMENTS First and foremost, I would like to thank my supervisors, General Carlo Magrassi and Professor Yulia Nikitina, as well as my co-supervisor, Professor Elena Sciso, for agreeing to support me in the choice of my topic for this thesis. Additionally, I would like to thank Doctor Simone Pasquazzi for his support and valuable advice. I would like to extend a special thank you to Colonel Cesario Totaro for his enthusiastic support for my thesis topic and for putting me in contact with key experts that provided useful information and advice. Furthermore, I am indebted to the experts of the UNODC, specifically Angela Me, Tofik Murshudlu, Andrea Mancini, Ekaterina Kolykhalova and to Lieutenant Colonel Arturo Sessa, as well as Commissario Paolo Sartori and Lieutenant Colonel Marco Molinari for providing invaluable information and for agreeing to answer my many questions.
    [Show full text]